HALL WALLACE L JR 4

What Happened Wallace L. Hall Jr., a director of Tvardi Therapeutics, was granted a derivative award covering 6,000 shares on June 9, 2026. The Form 4 reports the acquisition price as $0.00 (no cash paid at grant). This is a compensation award (not a purchase or sale) and does not represent an exercised option or an immediate sale of shares.

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 11, 2026 (timely filing).
• Securities acquired: derivative award for 6,000 shares; reported price $0.00.
• Shares owned after transaction: not provided in the supplied data.
• Footnote: 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the date of the issuer’s next annual meeting of stockholders, subject to the Reporting Person’s continuous service through that vesting date.
• No indication of a 10b5-1 plan, cashless exercise, or tax-withholding sale in the provided info.

Context This transaction is a standard equity-based compensation grant to a director. It’s essentially a retention/compensation award that vests on a single-cliff schedule (one year or at the next annual meeting) and does not signal an immediate buy or sell of stock. Retail investors should view this as part of director compensation rather than a direct vote of confidence via market purchase.